Company Profile
Amgen Inc. Stock Price, News & Analysis
- Ticker:
- AMGN
- Exchange:
- NASDAQ
- Sector:
- Biotechnology
- Location:
- Thousand Oaks, California
Why the stock is moving
AMGN is trading like a steady large-cap biotech name rather than a sharp event-driven move. Its diversified revenue base, recurring approval cycle, and the market's wait for the next earnings or regulatory update keep the stock anchored.
Company overview
Business overview
Amgen is a large-cap biopharmaceutical company with a commercial base spanning oncology, inflammation, bone health, cardiovascular disease, and rare disease. Investors follow the stock for the mix of marketed products, late-stage pipeline optionality, and recurring regulatory or launch milestones.
Geographic Base and Sector Classification
Headquartered in Thousand Oaks, California and listed on NASDAQ, Amgen is followed within the large-cap biotechnology universe for its exposure to diversified therapeutics and global commercial execution.
Business Model Characteristics
Amgen follows a hybrid model where commercial cash flow supports research, development, and business development. Launch execution, regulatory events, and portfolio refresh matter more than pure clinical-stage binary risk.
Position Within the Biotechnology Landscape
Compared with smaller clinical-stage peers, Amgen sits toward the more mature end of the biotech landscape, where cash generation, portfolio breadth, and execution consistency matter alongside catalysts.
Future catalysts
Amgen’s near-term catalysts are TEPEZZA subcutaneous development, Repatha’s cardiovascular growth, and any MariTide update that could reset the obesity narrative. The key question is whether the update shows enough repeatable demand to look like a durable revenue driver rather than a one-quarter bump. If adoption broadens, sentiment can improve faster than the reported numbers alone would suggest.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
FDA approves late-stage oncology treatment
Source: amgen.com
- 02
Management commentary keeps pipeline priorities in focus
Source: amgen.com
- 03
Investors watch oncology and cardiometabolic launch cadence
Source: newswire
- 04
Regulatory calendar keeps Amgen in the spotlight
Source: sec.gov
- 05
Pipeline updates reinforce the commercial-stage narrative
Source: conference
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What does Amgen Inc. do?
Amgen is a large-cap biopharmaceutical company with a commercial base spanning oncology, inflammation, bone health, cardiovascular disease, and rare disease. Investors follow the stock for the mix of marketed products, late-stage pipeline optionality, and recurring regulatory or launch milestones.
Where is Amgen Inc. based and where is the stock listed?
Amgen Inc. is listed on NASDAQ, Headquartered in Thousand Oaks, California and listed on NASDAQ, Amgen is followed within the large-cap biotechnology universe for its exposure to diversified therapeutics and global commercial execution., followed in 生物类似物,生物技术平台,肿瘤免疫治疗.
On which exchange is AMGN stock listed?
Amgen Inc. (AMGN) is associated with NASDAQ, Thousand Oaks, California, Biotechnology.
What is Amgen?
Amgen’s near-term catalysts are TEPEZZA subcutaneous development, Repatha’s cardiovascular growth, and any MariTide update that could reset the obesity narrative.
Which conditions is Amgen Inc. targeting with Amgen?
Amgen Inc. is associated with oncology, inflammatory disease, rare disease based on its company overview and current catalyst commentary.
How does Amgen Inc. describe recent progress with Amgen?
Amgen’s near-term catalysts are TEPEZZA subcutaneous development, Repatha’s cardiovascular growth, and any MariTide update that could reset the obesity narrative.
What is Investors?
Investors follow the stock for the mix of marketed products, late-stage pipeline optionality, and recurring regulatory or launch milestones.
What should investors watch for with Investors?
Amgen’s near-term catalysts are TEPEZZA subcutaneous development, Repatha’s cardiovascular growth, and any MariTide update that could reset the obesity narrative. The key question is whether the update shows enough repeatable demand to look like a durable revenue driver rather than a one-quarter bump. If adoption...
What is Repatha?
Amgen’s near-term catalysts are TEPEZZA subcutaneous development, Repatha’s cardiovascular growth, and any MariTide update that could reset the obesity narrative.